No Data
BTIG Maintains Biogen(BIIB.US) With Hold Rating
Goldman Sachs Adjusts Price Target on Biogen to $281 From $290, Keeps Buy Rating
Biogen's Hold Rating: Balancing Modest Gains and Strategic Uncertainty
Biogen, Eisai Receive US FDA Biologics Approval for Leqembi Dosing
Reported Sunday, Eisai And Biogen Achieve FDA Approval For LEQEMBI IV Maintenance Dosing, Reducing Treatment Frequency For Early Alzheimer's Patients
Express News | FDA Approves Leqembi® (Lecanemab-Irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease